Murepavadin: Physiology and What Research Reports

What murepavadin is

Murepavadin is a synthetic peptidomimetic antibiotic — a chemically engineered cyclic peptide designed to copy part of the shape of a natural host defence peptide rather than to reproduce a human hormone. A 2018 review described murepavadin as the first clinical representative of a new antibiotic class, the outer membrane protein targeting antibiotics (OMPTA), developed from protein epitope mimetic chemistry and directed specifically at Pseudomonas aeruginosa (PMID 29451043).

This distinguishes murepavadin from most molecules in a peptide physiology library. There is no gland, tissue or cell that produces murepavadin, and it has no described endogenous receptor signalling role in normal human physiology. Its "physiology" is bacterial: what it does to the outer membrane of a Gram-negative organism, and what happens in a host when it is infused. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about infection, antibiotics or treatment.

How it is made

Because murepavadin is a macrocyclic peptide, its manufacture is a synthetic chemistry problem rather than a fermentation one. A 2024 synthesis paper reported the preparation of murepavadin using novel coupling agents, describing the peptide as an antimicrobial agent whose assembly depends on efficient amide bond formation during solid-phase and cyclisation steps (PMID 38785933). Papers of this kind matter to readers who encounter the name, because synthetic accessibility is one of the practical constraints on peptidomimetic drug development.

Mechanism: LptD and lipopolysaccharide transport

The 2018 review reported that murepavadin acts on LptD, an outer membrane protein involved in transporting lipopolysaccharide (LPS) to the bacterial surface, giving the compound a mechanism distinct from established antibiotic classes and a narrow spectrum focused on P. aeruginosa (PMID 29451043). A 2024 mechanistic study examining murepavadin resistance reported that resistant P. aeruginosa showed lipopolysaccharide alterations, and the authors traced downstream consequences of those changes for the bacterial envelope (PMID 39711784).

Envelope effects also appear to influence how other antibiotics behave. A 2024 study reported that murepavadin promoted the killing efficacy of aminoglycoside antibiotics against P. aeruginosa, and researchers attributed the effect to enhanced membrane potential, which increases aminoglycoside uptake (PMID 38470195).

How murepavadin is studied

The published literature on murepavadin uses a fairly standard antibacterial toolkit:

• Minimum inhibitory concentration (MIC) testing against large collections of clinical isolates, used in surveillance studies of P. aeruginosa from the United States, Europe and China (PMID 29686157).
• Comparator panels, in which murepavadin is tested alongside conventional agents; one 2020 study compared murepavadin with 13 comparator antibiotics against isolates recovered from people with cystic fibrosis (PMID 31767727).
• Biofilm assays, which assess activity against surface-attached bacterial communities rather than free-floating cells (PMID 34283223).
• Resistance selection experiments and sequencing of resistant mutants (PMID 33367642, PMID 39711784).
• Animal pharmacokinetic/pharmacodynamic (PK/PD) modelling, typically neutropenic mouse thigh and lung infection models (PMID 30642931).
• Human Phase 1 pharmacokinetics, using single and multiple ascending intravenous infusions in healthy adults (PMID 29437621).

What the Literature Reports

Activity against clinical isolates

A 2018 surveillance study tested murepavadin against clinical P. aeruginosa isolates collected in the United States, Europe and China and reported antimicrobial activity across those geographically distinct collections (PMID 29686157). A companion 2018 report tested murepavadin against contemporary 2016–17 clinical isolates classified as extensively drug-resistant (XDR) P. aeruginosa, a group in which conventional options are limited (PMID 29901750). In cystic fibrosis isolates, the study comparing murepavadin with 13 comparator antibiotics reported susceptibility data for that population specifically (PMID 31767727).

Biofilms and resistance

A 2021 study examined anti-biofilm activity of murepavadin against cystic fibrosis P. aeruginosa isolates, extending testing beyond standard broth MICs (PMID 34283223). A separate 2021 paper reported both antimicrobial activity and resistance development in cystic fibrosis P. aeruginosa isolates, indicating that resistance can be selected under laboratory pressure (PMID 33367642). The 2024 mechanism paper reported that lipopolysaccharide alterations underlay murepavadin resistance in the strains studied (PMID 39711784).

Pharmacokinetics and pharmacodynamics

Researchers reported PK and PD characterisation of murepavadin in neutropenic mouse models in a 2019 paper, the type of analysis used to identify which exposure measure best tracks bacterial killing (PMID 30642931). In humans, a 2018 Phase 1 report described the pharmacokinetics and safety of intravenous murepavadin infusion in healthy adult subjects given single and multiple ascending doses (PMID 29437621).

Murepavadin and Adverse Events: What Studies Report

Two lines of published work bear on tolerability. The 2018 Phase 1 study reported on the safety of intravenous murepavadin infusion in healthy adult subjects across single and multiple ascending dose cohorts, alongside its pharmacokinetic measurements (PMID 29437621).

Separately, a 2021 immunology study reported that murepavadin, described as a small molecule host defence peptide mimetic, activated mast cells via the receptors MRGPRX2 in humans and MrgprB2 in mice (PMID 34248979). MRGPRX2 is the receptor family associated with non-IgE, pseudo-allergic reactions to several cationic peptide drugs, so researchers use this readout to anticipate infusion-type reactions in preclinical screening (PMID 34248979).

Readers should note the boundary of this evidence: the papers summarised here are laboratory, animal and Phase 1 reports. Murepavadin is an investigational compound and is not an approved medicine; nothing above should be read as a tolerability profile for clinical use, and any adverse-event question belongs with a physician and the full regulatory record.

Why the term matters to peptide readers

Murepavadin is frequently cited as a proof of concept that peptide chemistry can produce a target-specific antibacterial agent with a genuinely novel mechanism, rather than a membrane-lysing generalist (PMID 29451043). It also illustrates three recurring themes in peptide research literature: synthesis difficulty (PMID 38785933), off-target receptor engagement by cationic peptides (PMID 34248979), and the speed with which bacteria can remodel a target pathway (PMID 39711784).

Limitations of the evidence

Most murepavadin data come from in vitro isolate testing and rodent infection models. Isolate surveillance describes potency, not clinical outcome; neutropenic mouse PK/PD informs exposure targets, not human efficacy (PMID 30642931). Resistance studies show that selection is possible under laboratory conditions (PMID 33367642), and mast cell findings are receptor-level observations rather than clinical event rates (PMID 34248979).

References

• Murepavadin: a new antibiotic class in the pipeline (Expert Review of Anti-Infective Therapy, 2018)
• Unravelling the mechanisms causing murepavadin resistance in Pseudomonas aeruginosa: lipopolysaccharide alterations and its consequences (Frontiers in Cellular and Infection Microbiology, 2024)
• Synthesis of the Antimicrobial Peptide Murepavadin Using Novel Coupling Agents (Biomolecules, 2024)
• Murepavadin promotes the killing efficacies of aminoglycoside antibiotics against Pseudomonas aeruginosa by enhancing membrane potential (Antimicrobial Agents and Chemotherapy, 2024)
• Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa (Journal of Antimicrobial Chemotherapy, 2018)
• Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of Pseudomonas aeruginosa from the United States, Europe, and China (Antimicrobial Agents and Chemotherapy, 2018)
• Susceptibility of Pseudomonas aeruginosa Recovered from Cystic Fibrosis Patients to Murepavadin and 13 Comparator Antibiotics (Antimicrobial Agents and Chemotherapy, 2020)
• Murepavadin antimicrobial activity against and resistance development in cystic fibrosis Pseudomonas aeruginosa isolates (Journal of Antimicrobial Chemotherapy, 2021)
• Anti-biofilm activity of murepavadin against cystic fibrosis Pseudomonas aeruginosa isolates (Journal of Antimicrobial Chemotherapy, 2021)
• Pharmacokinetics and Pharmacodynamics of Murepavadin in Neutropenic Mouse Models (Antimicrobial Agents and Chemotherapy, 2019)
• Pharmacokinetics and Safety of Intravenous Murepavadin Infusion in Healthy Adult Subjects Administered Single and Multiple Ascending Doses (Antimicrobial Agents and Chemotherapy, 2018)
• Murepavadin, a Small Molecule Host Defense Peptide Mimetic, Activates Mast Cells via MRGPRX2 and MrgprB2 (Frontiers in Immunology, 2021)